ANNX
vs
S&P 500
ANNX
S&P 500
Over the past 12 months, ANNX has underperformed S&P 500, delivering a return of +14% compared to the S&P 500's +18% growth.
Stocks Performance
ANNX vs S&P 500
Performance Gap
ANNX vs S&P 500
Performance By Year
ANNX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Annexon Inc
Glance View
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 61 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Its pipeline includes three clinical-stage assets across three therapeutic franchises: Autoimmune, Neurodegeneration and Ophthalmology. Its lead candidate, ANX005, is a monoclonal antibody formulated for intravenous administration for several autoimmune indications. ANX005 is being evaluated in a Phase II/III clinical trial for the treatment of patients with Guillain-Barre Syndrome and a Phase II trial in patients with warm autoimmune hemolytic anemia. The company ANX009 clinical candidate is a subcutaneous formulation of an antigen-binding fragment, which is evaluates in a Phase I trial. The company is also developing ANX005, which is in Phase II trials in Huntington’s disease and amyotrophic lateral sclerosis. The firm's ANX007 program is a Fab formulated.
